Enthesitis in a European registry-based cohort of patients with psoriatic arthritis treated with tumour necrosis factor inhibitors: clinical burden, patient-reported outcomes, and treatment response (vol 53, pg 237, 2024)

被引：0
|
作者：
Mathew, A. J.
Hetland, M. L.
Pedersen, M. P.
Rasmussen, S. H.
Glintborg, B.
Loft, A. G.
Nissen, M. J.
Moller, B.
Rodrigues, A. M.
Santos, F. P.
Rotar, Z.
Tomsic, M.
Relas, H.
Peltomaa, R.
Gudbjornsson, B.
Love, T. J.
Kocaer, S. B.
Avsar, A. Koken
Midtboll Ornbjerg, L.
Ostergaard, M.
机构：
来源：
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY | 2024年 / 53卷 / 05期
关键词：
D O I：
10.1080/03009742.2024.2377498
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：368 / 368
页数：1
相关论文
共 34 条
  • [1] Enthesitis in a European registry-based cohort of patients with psoriatic arthritis treated with tumour necrosis factor inhibitors: clinical burden, patient-reported outcomes, and treatment response
    Mathew, A. J.
    Lund, M. L.
    Pedersen, M. P.
    Rasmussen, S. H.
    Glintborg, B.
    Loft, A. G.
    Nissen, M. J.
    Moller, B.
    Rodrigues, A. M.
    Santos, F. P.
    Rotar, Z.
    Tomsic, M.
    Relas, H.
    Peltomaa, R.
    Gudbjornsson, B.
    Loeve, T. J.
    Kocaer, S. B.
    Avsar, A. Koken
    Ornbjerg, L. Midtboll
    Ostergaard, M.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2024, 53 (04) : 237 - 247
  • [2] IXEKIZUMAB IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR-INHIBITORS
    Kavanaugh, A.
    Vender, R.
    Birt, J.
    Adams, D. H.
    Benichou, O.
    Lin, C. -Y.
    Nash, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 941 - 941
  • [3] Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
    Mease, Philip J.
    Karki, Chitra
    Palmer, Jacqueline B.
    Etzel, Carol J.
    Kavanaugh, Arthur
    Ritchlin, Christopher T.
    Malley, Wendi
    Herrera, Vivian
    Tran, Melody
    Greenberg, Jeffrey D.
    ARTHRITIS CARE & RESEARCH, 2017, 69 (11) : 1692 - 1699
  • [4] TIME TO RESPONSE FOR CLINICAL AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH TOFACITINIB, ADALIMUMAB OR PLACEBO
    Gladman, D. D.
    Coates, L. C.
    Wu, J.
    Fallon, L.
    Hsu, M. A.
    Bushmakin, A. G.
    Bacci, E.
    Cappelleri, J. C.
    Helliwell, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1681 - 1681
  • [5] Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
    Gladman, Dafna D.
    Coates, Laura C.
    Wu, Joseph
    Fallon, Lara
    Bacci, Elizabeth D.
    Cappelleri, Joseph C.
    Bushmakin, Andrew G.
    Helliwell, Philip S.
    ARTHRITIS RESEARCH & THERAPY, 2022, 24 (01)
  • [6] Time to Response for Clinical and Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Tofacitinib, Adalimumab, or Placebo
    Gladman, Dafna
    Coates, Laura
    Wu, Joseph
    Fallon, Lara
    Hsu, Ming-Ann
    Bushmakin, Andrew
    Bacci, Elizabeth
    Cappelleri, Joseph
    Helliwell, Philip
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [7] Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
    Dafna D. Gladman
    Laura C. Coates
    Joseph Wu
    Lara Fallon
    Elizabeth D. Bacci
    Joseph C. Cappelleri
    Andrew G. Bushmakin
    Philip S. Helliwell
    Arthritis Research & Therapy, 24
  • [8] Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks
    Kavanaugh, A.
    Marzo-Ortega, H.
    Vender, R.
    Wei, C. -C.
    Birt, J.
    Adams, D. H.
    Benichou, O.
    Lin, C. -Y.
    Nash, P.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2019, 37 (04) : 566 - 574
  • [9] Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond
    Strand, Vibeke
    de Vlam, Kurt
    Covarrubias-Cobos, Jose A.
    Mease, Philip J.
    Gladman, Dafna D.
    Chen, Linda
    Kudlacz, Elizabeth
    Wu, Joseph
    Cappelleri, Joseph C.
    Hendrikx, Thijs
    Hsu, Ming-Ann
    RMD OPEN, 2019, 5 (01):
  • [10] Correlation of patient preferences to treatment outcomes in patients with rheumatoid arthritis treated with tumour necrosis factor inhibitors in Greece
    Prodromos Sidiropoulos
    Andreas Bounas
    Panagiotis Athanassiou
    Christos Koutsianas
    Evangelia Petrikkou
    Evripidis Kaltsonoudis
    Alexandros Drosos
    Dimitrios Vassilopoulos
    Clinical Rheumatology, 2020, 39 : 3643 - 3652
1234